Medium dose group:Recommended dose

2 trials

Sponsors

The First Affiliated Hospital of Anhui Medical University, the Second Affiliated Hospital of Soochow University

Conditions

CD19 positive B cell malignant tumorGlioma

Early Phase 1

To evaluate the safety and tolerability of CD19 UCAR-T cell injection in subjects with relapsed/refractory CD19-positive B-cell malignancies

Active, not recruitingChiCTR2100052434

The First Affiliated Hospital of Anhui Medical UniversityCD19 positive B cell malignant tumor

Start: 2021-10-11Updated: 2022-10-17

To evaluate the safety and effectiveness of targeting IL-13Ra2 or B7-H3 UCAR-T cell injection in the treatment of advanced glioma

Active, not recruitingChiCTR2100052448

the Second Affiliated Hospital of Soochow UniversityGlioma

Start: 2021-11-12Updated: 2022-10-17